

**METHOD FOR INHIBITING ADENYLOSUCCINATE SYNTHETASE
ACTIVITY METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT
CELLS**

5

Cross Reference To Related Applications

This is a continuation-in-part of U.S. Patent Application
Serial No. 08/176,855, filed December 29, 1993, now
10 pending.

Background of the Invention

The invention relates to pharmaceutical agents and
15 methods for use in chemotherapeutic treatment of cancer.
More specifically, the invention relates to the
identification of cancer cells which cannot metabolize
methylthioadenosine phosphorylase to adenine for the
salvage synthesis of adenine nucleotides, and the use of
20 L-alanosine to inhibit de novo adenosine 5'-monophosphate
(AMP) synthesis in such cancer cells.

History of the Invention

25 Methylthioadenosine (MTA) is cleaved in healthy mammalian
cells by methylthioadenosine phosphorylase (MTase) into
adenine and methylthioribose-1-P, the latter of which is
a substrate for metabolic synthesis of methionine.
Adenine is salvaged into a cellular pool of adenosine 5'-
30 monophosphate (AMP), from which cells derive adenosine
5'-triphosphate (ATP) for metabolic energy and 2'-
deoxyadenosine-5'-triphosphate (dATP) for DNA synthesis.

Based on early in vitro studies, the L isomer of a
35 bacterial antibiotic alanosine (obtained from
Streptomyces alanosinicus; hereafter, "L-alanosine")
appeared to have promise for use as an anti-viral and

anti-tumor agent. In particular, it is believed that L-alanosine inhibits adenylosuccinate synthetase (ASS) conversion of inosine 5'-monophosphate (IMP) to AMP, thus depleting target cells of AMP and ATP (in the absence of adenine). However, clinical studies of the therapeutic efficacy of L-alanosine in human cancer patients have been disappointing (see, e.g., data collected in Tyagi and Cooney, *Adv. Pharmacol. Chemotherapy*, 20:69-120, 1984 [results then to date offered "little encouragement" regarding L-alanosine's efficacy for treatment of human cancers]; Creagan, et al., *Cancer*, 52:615-618, 1993 [Phase II studies had overall response rate of only 4%]; Creagan, et al., *Am.J.Clin.Oncol.*, 7:543-544, 1984 [Phase II study in melanoma patients; little therapeutic response observed]; VonHoff, et al., *Invest. New Drugs*, 9:87-88, 1991 [no objective responses observed in breast cancer patients])). Eventually, all clinical trials of L-alanosine for use in treatment of cancer were abandoned.

20

Another known inhibitor of ASS activity is hadacidin. However, hadacidin is believed to be more toxic than L-alanosine in humans. Further, the activity of other inhibitors of *de novo* purine synthesis (such as methotrexate, 6-mercaptopurine, 6-thioguanine and d-ideazetetrahydrofolate) which block IMP synthesis (and therefore theoretically eliminate IMP as a source for AMP production) has been circumvented *in vivo* by salvage of hypoxanthine, which is abundant in plasma, for use as a substrate for IMP production. Hence, to date the *in vivo* performance of agents which block the adenine metabolic pathway for intracellular AMP production has been frustratingly poor.

35 However, with the development of an assay of sufficient sensitivity to identify homozygous deletions of the gene encoding MTase in certain human cancer cells (see,

commonly assigned parent U.S. Patent Application Serial No. 08/176,855), it now appears that the tumors treated in the clinical trials of L-alanosine produced MTase and were therefore able to provide sufficient adenine to maintain a pool of AMP despite inhibition of AMP production from IMP. The present invention therefore provides a method for identifying cells which lack MTase and for treating such cells by depleting them of AMP.

10 Summary of the Invention

It has been discovered that cells from which the gene which encodes MTase protein has been deleted and are therefore not able to metabolize MTA to adenine ("MTase
15 deficient cells") are selectively killed *in vivo* on contact with therapeutically effective dosages of a *de novo* AMP synthesis inhibitor such as L-alanosine. Thus, while L-alanosine is not therapeutically effective against all cancer cells, it is therapeutically effective
20 against MTase deficient cells.

In one aspect, the invention provides a method for determining whether particular cancer cells are MTase deficient by providing assays to determine whether the
25 cells lack MTase protein. The preferred assay for use in this regard is one for detection of homozygous deletions from cells of the gene which encodes MTase protein.

In another aspect, the invention provides a method for treating MTase deficient cancers by contacting MTase deficient cells with a therapeutically effective amount of a *de novo* purine synthesis inhibitor which inhibits the activity of ASS, preferably L-alanosine. The ASS inhibitory agents of the invention may be administered by any clinically acceptable means, but are preferably administered by continuous infusion at concentrations below the maximally tolerated dose to prolong the desired

inhibitory activity and minimize toxicity to host tissues.

Also provided are kits for use in the methods of the invention which include reagents for use in performing the MTase deficiency assay of the invention as well as pharmaceutical compositions of an ASS inhibitor, preferably L-alanosine and/or its active metabolite, L-alanosinyl AICOR.

10

Brief Description of the Drawing

FIGURE 1 is a nucleotide sequence for genomic MTase (SEQ.ID.No.1) wherein the exons are underlined.

15

FIGURE 2 is a graph depicting the *in vivo* effect of L-alanosine after continuous infusion on established human MTase competent and MTase deficient non-small cell lung cancer xenograft tumors in nude mice.

20

FIGURE 3 is a graph depicting the *in vivo* effect of L-alanosine after continuous infusion on established human MTase deficient acute lymphoblastic leukemia xenograft tumors in nude mice.

25

FIGURES 4 and 5 (A-B) are graphs depicting the effect of administering various exogenous MTase substrates to MTase competent or MTase deficient cell lines after treatment with L-alanosine.

30

FIGURE 6 is a schematic depiction of the intracellular metabolic pathways for production of AMP.

FIGURE 7 is a graph depicting the *in vivo* effect of L-alanosine after daily injection on established human MTase deficient non-small cell lung cancer xenograft tumors in nude mice.

Description of the Preferred Embodiments**I. METABOLIC PATHWAYS FOR INTRACELLULAR PRODUCTION OF AMP**

5

To assist in understanding the invention, a chart depicting the intracellular metabolic pathways by which AMP is produced is provided in FIGURE 6. In summary, there are three principal sources of substrates for intracellular AMP production. The first is catabolism of methylthioadenosine to adenine by MTase. This pathway is blocked in MTase deficient cells.

The second is conversion of IMP to AMP by the activity of ASS or adenylosuccinate lyase (ASL). There are presently no known inhibitors of ASL activity. However, with loss of ASS activity, IMP AMP conversion is substantially eliminated.

The third is hypoxanthine salvage to AMP. However, because IMP AMP conversion occurs distal to hypoxanthine salvage, inhibition of ASS catabolism of IMP AMP blocks the hypoxanthine salvage pathway.

II. METHOD FOR DETERMINING WHETHER TUMOR CELLS IN AN ASSAYABLE SAMPLE OBTAINED FROM A MAMMALIAN HOST ARE MTase DEFICIENT**A. Polynucleotide Reagents for Use in Identifying MTase Deficient Cells**

30

The preferred method for determining whether a particular population of cells are MTase deficient is by hybridization assay to detect homozygous deletions of the gene which encodes MTase from the cells. Screening procedures which rely on nucleic acid hybridization make it possible to detect any polynucleotide sequence (and,

by inference, any protein encoded by such polynucleotide sequence) in any organism, provided the appropriate probe is available.

5 A complete description of hybridization techniques suitable for use in the invention, as well as a description of the gene which encodes MTase, are set forth in co-pending, commonly assigned U.S. Patent Application Serial No. 08/176,855 (filed December 29,
10 1993), the disclosure of which is incorporated herein by this reference together with any amendments which may be made thereto. For ease of reference, the polynucleotide sequence of the gene which encodes MTase is described herein at SEQ.ID.No.1 in the appended Sequence Listing
15 and in FIGURE 1, where coding regions of the gene are identified by underlining.

Genomic MTase polynucleotide is located on chromosome 9 at region p21. Interestingly, a very high percentage of cells which have a homozygous deletion of the gene which
20 encodes tumor suppressor p16 also have a homozygous deletion of the gene which encodes MTase. Thus, an alternative means of detecting homozygous deletions of the latter gene (for MTase) is by detecting a homozygous deletion of the former gene (for p16). For further
25 reference in this regard, see commonly assigned, co-pending U.S. Patent Application Serial No. 08/227,800, the disclosure of which is incorporated herein by this reference.

30 A strain of *E. coli* containing the full-length genomic DNA for rat MTase was deposited with the American Type Culture Collection, Rockville, MD. by mailing before December 29, 1993 and accorded, collectively, Designation Nos. 55536, 55537, 55538, 55539 and 55540. No admission
35 that this deposit is necessary to enable one to practice the invention is made or intended. The deposit will, however, be maintained in viable form for whatever period

is or may be required by the patent laws applicable to this disclosure.

To determine whether the MTase gene has been homozygously
5 deleted from the cells of interest, an assayable sample
of cells is obtained from the host. For example, the
sample may comprise a body fluid or cells, e.g., from a
host tissue or tumor. Such samples are obtained using
methods known in the clinical art, e.g., tumor cells may
10 be acquired by biopsy or surgical resection. Preferably,
the cells are essentially free from "contaminants"; i.e.,
cells, proteins and similar components which could
falsify the result of the assay. For example, where solid
tumors are the source for an assayable cell sample,
15 normal non-malignant cells and the MTase which may be
released from normal cells during the procedure performed
to obtain the biological sample would be considered to be
contaminants. Such contaminants may be removed by
conventional purification techniques; e.g., affinity
20 chromatography with an anti-MTase antibody.

Because the invention is directed toward detecting the
presence or absence of this gene in a sample of cells
which are suspected of being MTase negative, nucleic
25 acids in the sample will preferably be amplified to
enhance the sensitivity of the detection method. This
amplification is preferably accomplished through the use
of the polymerase chain reaction (PCR), although the use
of a chain reaction in the polymerization step is not
30 absolutely necessary.

The nucleic acid to be amplified in the sample will
consist of genomic or wild-type DNA that would normally
be expected to encode MTase if present in the sample
35 (see, SEQ.ID.No.1). MTase encoding DNA (hereafter the
"target DNA") is believed to be present in all normal
mammalian cells, including human cells.

For use as a control or as a source of oligonucleotide probes and primers, genomic MTase-encoding DNA may be isolated according to methods known in the art such as the method described by Maniatis, et al. in *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, 1982). A working example demonstrating the isolation of a genomic clone of the human MTase gene is provided herein wherein a cosmid gene library is screened using an MTase cDNA oligonucleotide probe (see, Example III). However, those skilled in the art will recognize that other suitable means of obtaining MTase encoding DNA can be used.

For example, a cDNA library believed to contain a polynucleotide of interest can be screened by injecting various mRNA derived from cDNAs into oocytes, allowing sufficient time for expression of the cDNA gene products to occur, and testing for the presence of the desired cDNA expression product, for example, by using antibody specific for a peptide encoded by the polynucleotide of interest or by using probes for the repeat motifs and a tissue expression pattern characteristic of a peptide encoded by the polynucleotide of interest. Alternatively, a cDNA library can be screened indirectly for expression of peptides of interest (e.g., MTase protein) having at least one epitope using antibodies specific for the peptides. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of cDNA of interest (see, for further reference, Maniatis, et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab., New York, 1982)).

Polynucleotides for use as controls, probes or primers in the invention can also be synthesized using techniques and nucleic acid synthesis equipment which are well-known in the art. For reference in this regard, see Ausubel, et

al., *Current Protocols in Molecular Biology*, Chs. 2 and 4 (Wiley Interscience, 1989).

5 B. Amplification of MTase Encoding Genomic DNA and Hybridization Assay Therefor

10 To enhance the sensitivity of the hybridization assays of the invention, the cell sample to be assayed is preferably subjected to conditions favoring the selective amplification of the target nucleic acid. Preferably, the target nucleic acid will be a polynucleotide portion of the gene which encodes MTase (i.e., the "target polynucleotide"). The preferred means of amplifying the target polynucleotide is by PCR.

15 PCR is an *in vitro* method for the enzymatic synthesis of specific DNA or RNA sequences using oligonucleotide primers that hybridize to specific nucleic acid sequences and flank the region of interest in target nucleic acid.

20 A repetitive series of cycles of template denaturation, primer annealing and enzymatic extension of the annealed primers results in an exponential accumulation of a specific nucleic acid fragment defined at its termini by the 5' ends of the primers. The resulting products (PCR

25 products) synthesized in one cycle act as templates for the next; consequently, the number of target nucleic acid copies approximately doubles in every cycle.

30 The basic PCR techniques are described in U.S. Patent 4,683,195 and 4,683,202 to Mullis, et al., the disclosures of which are incorporated herein as examples of the conventional techniques for performance of the PCR. However, the invention is not intended to be limited to the use of the PCR techniques which are taught

35 in the '202 patent to Mullis, et al.. Since the development of the Mullis, et al. technique, many PCR based assays have been developed which utilize

modifications of that technique. These modifications are well-known in the art and will not, therefore, be described in detail here. However, for the purpose of illustrating the scope of the art in this field, several
5 of these modifications are described as follows.

A PCR technique which provides an internal amplification standard using a competitor template which differs from the target nucleic acid in sequence and size is described
10 in *Proc. Natl. Acad. Sci. USA* (1990) 87:2725-2729 (Gilliland, et al., authors). Another technique for performing "competitive" PCR which utilizes templates which differ in sequence but not in size is described in
Nuc. Acids. Res., 21:3469-3472, (1993), (Kohsaka, et al.
15 , authors). This technique is a particularly preferred technique for its use of enzyme-linked immunoabsorbent assay (ELISA) technology to analyze the amplified nucleic acid(s). A noncompetitive PCR technique which utilizes site-specific oligonucleotides to detect mutations or
20 polymorphisms in genes which may also be applied to the method of the invention is described in *Proc. Natl. Acad. Sci. USA* (1989) 86:6230-6234 (Saiki, et al., authors). Each of these techniques has the advantage of utilizing hybridization probes which assist in eliminating false
25 positive results derived from any nonspecific amplification which may occur during the PCR.

For further background, those skilled in the art may wish to refer to Innis, et al., "Optimization of PCR's", PCR
30 Protocols: A Guide to Methods and Applications (Acad. Press, 1990). This publication summarizes techniques to influence the specificity, fidelity and yield of the desired PCR products.

35 Oligonucleotide primers (at least one primer pair) are selected which will specifically hybridize to a small stretch of base pairs on either side (i.e., 5' and 3') of

the MTase target polynucleotide (i.e., "flanking sequences"). Those skilled in the art will readily be able to select suitable primers without undue experimentation based on the polynucleotide sequence information set forth in the Sequence Listing appended hereto as SEQ. ID. No. 1 and in FIGURE 1.

For primer design, it is important that the primers do not contain complementary bases such that they could hybridize with themselves. To eliminate amplification of any contaminating material which may be present in the sample, primers are preferably designed to span exons (which, for the MTase gene, are underlined in FIGURE 1).

As noted above, it may not be necessary to utilize the chain reaction in this polymerization step in order to adequately amplify the nucleic acids in the sample. For example, where the technique described by Kohsaka, et al., *supra* is utilized so the polymerization step is performed on solid phase support means and is followed by hybridization with target polynucleotide specific probes, the sensitivity of the assay will be such that a single polymerization of the target polynucleotide may be all that is necessary.

Once the amplification step is complete, the PCR products are assayed to determine thereby whether the gene to encode MTase is present in the sample. Preferably, the double-stranded PCR products will be bound to the solid phase so their strands may be separated by denaturation, thereby allowing sequence-specific probes to hybridize to the bound antisense strand of the PCR product to detect the gene substantially as described in Kohsaka, et al., *supra*. Alternatively, the PCR products will be removed from the reaction environment and separated from the amplification mixture prior to the addition of probes for hybridization to the double-stranded PCR products. In

this latter approach, the PCR products are separated from the amplification mixture according to methods known in the art with regard to the particular method chosen for detection; e.g., by gel exclusion, electrophoresis or
5 affinity chromatography.

Detection of the amplified product may be achieved by using hybridization probes which are stably associated with a detectable label. A label is a substance which
10 can be covalently attached to or firmly associated with a nucleic acid probe which will result in the ability to detect the probe. For example, a label may be a radioisotope, an enzyme substrate or inhibitor, an enzyme, a radiopaque substance (including colloidal
15 metals), a fluorescers, a chemiluminescent molecule, liposomes containing any of the above labels, or a specific binding pair member. A suitable label will not lose the quality responsible for detectability during amplification.

20 Those skilled in the diagnostic art will be familiar with suitable detectable labels for use in in vitro detection assays. For example, suitable radioisotopes for in vitro use include ^3H , ^{125}I , ^{131}I , ^{32}P , ^{14}C , ^{35}S . Amplified fragments
25 labeled by means of a radioisotope may be detected directly by gamma counter or by densitometry of autoradiographs, by Southern blotting of the amplified fragments combined with densitometry. Examples of suitable chemiluminescent molecules are acridines or
30 luminol. Target sequences hybridized with probes derivatized with acridium ester are protected from hydrolysis by intercalation. Examples of suitable f-luorescers are fluorescein, phycobiliprotein, rare earth chelates, dansyl or rhodamine.

35 Examples of suitable enzyme substrates or inhibitors are compounds which will specifically bind to horseradish

peroxidase, glucose oxidase, glucose-6-phosphate dehydrogenase, β -galactosidase, pyruvate kinase or alkaline phosphatase acetylcholinesterase. Examples of radiopaque substance are colloidal gold or magnetic
5 particles.

A specific binding pair comprises two different molecules, wherein one of the molecules has an area on its surface or in a cavity which specifically binds to a
10 particular spatial and polar organization of another molecule. The members of the specific binding pair are often referred to as a ligand and receptor or ligand and anti-ligand. For example, if the receptor is an antibody the ligand is the corresponding antigen. Other specific
15 binding pairs include hormone-receptor pairs, enzyme substrate pairs, biotin-avidin pairs and glycoprotein-receptor pairs. Included are fragments and portions of specific binding pairs which retain binding specificity, such a fragments of immunoglobulins, including Fab
20 fragments and the like. The antibodies can be either monoclonal or polyclonal. If a member of a specific binding pair is used as a label, the preferred separation procedure will involve affinity chromatography.

25 If no amplified product can be detected in the assay described above, this is indicative of MTase deficiency in the cells present in the sample. Because normal (i.e., nonmalignant) cells will always be expected to have MTase encoding gene present in detectable quantities
30 (even with loss of one allele), a finding that cells lack an MTase encoding gene (i.e., have a homozygous deletion of the gene) indicates that the cells assayed lack both catalytically active and catalytically inactive MTase.

35 However, where desired, the sample can be prescreened for MTase catalytic activity using the method described by Seidenfeld, et al., *Biochem. Biophys. Res. Commun.*,

95:1861-1866 (1980); see also, Example I, *infra*). The inventive assay will then be used to determine whether the gene encoding MTase is present in cells in the sample. The sample may also be tested for the presence
5 of catalytically active or inactive protein for the purpose of screening out cellular contaminants in the sample to be assayed; i.e., nonmalignant cells. A suitable immunoassay for alternative use in this regard (i.e., in lieu of the hybridization assay) is described
10 in Nobori, et al., *Cancer Res.* 53:1098-1101 (1991) and in co-pending, commonly assigned U.S. patent application Serial No. 08/177,855 filed on December 29, 1993, the disclosure of which has been incorporated herein.

15 C. MTase Deficient Cells

Using the assay techniques described above, the following human primary tumors have been determined to be MTase deficient. It will be understood that this list is
20 representative, but not exhaustive, of the cancer types which may be determined to be MTase deficient using the assay methods described.

- Acute lymphoblastic leukemias (approximately 80%
25 occurrence)
- Gliomas (approximately 67% occurrence)
- Non-small cell lung cancers (approximately 18% occurrence)
- Urothelial tumors (e.g., bladder cancer; incidence
30 varies with tumor type)

Based on these data, MTase deficiency should be strongly suspected of patients suffering from these conditions. Thus, cell samples from such patients should be routinely
35 assayed for MTase deficiency to determine whether the patient would be likely to benefit from the therapeutic method of the invention.

Cell samples from other cancer patients should be assayed for MTase deficiency as clinically indicated. For reference, primary tumor samples from patients suffering from the following conditions have not been found to be
5 MTase deficient (i.e., the cancers are "MTase competent"):

- Breast cancer
- Colon cancer
- 10 • Head and Neck cancer
- Melanoma
- Renal cancer
- Adult non-lymphoblastic leukemias
- Certain acute leukemias (adult and juvenile)

15

Clinical trials have been conducted using L-alanosine to treat the above-listed MTase competent cancers, with no appreciable success.

20 II. METHOD FOR TREATMENT OF MTase DEFICIENT CELLS

A. Pharmacology and Toxicity Parameters for L-alanosine

25 In primates, approximately 75% of L-alanosine is excreted in urine in about 24 hours, primarily as the nucleoside forms of L-alanosinyl-IMP and L-alanosinyl-AICOR. Clearance from plasma after intravenous administration in humans is biphasic, with $t_{1/2\alpha}=14$ minutes and $t_{1/2\beta}=99$ minutes
30 (where " $t_{1/2}$ " is the half-life and times (t) are approximate).

In prior clinical trials, toxicity has been dose-limiting, including renal toxicity, stomatitis,
35 esophagitis and, with lesser frequency, myelosuppression, headache, nausea and hypo- or hypertension. Renal toxicity occurred with single bolus dosing above 4 g/m²

body weight. Further, two pediatric patients who received higher doses of about 350 mg/m² body weight per day in separate doses suffered liver failure. Stomatitis and esophagitis occurred after multiple bolus dosing. The
5 other observed reactions were patient specific.

One phase II trial utilized continuous infusion at a dose of about 125 mg/m² body weight for 5 days in adults suffering from acute non-lymphoblastic leukemia. The dose
10 limiting toxicity was mucositis.

B. Administration of ASS Inhibitors to a Host

Mammalian hosts (e.g., humans) suffering from cancers
15 determined to be MTase deficient according to the MTase deficiency assay of the invention are treated with therapeutically effective dosages of an ASS inhibitor such as L-alanosine, L-alanosinyl-AICOR or hadacidin, preferably the former. In this respect, a
20 "therapeutically effective dosage" is one which produces an objective tumor response in evaluable patients, where tumor response is a cessation or regression in growth determined against clinically accepted standards (see, e.g., Eagan, et al., Cancer, 44:1125-1128, 1979 [the
25 disclosure of which is incorporated herein by this reference] and the publicly available reports of parameters applied (essentially per Eagan, et al.) in the clinical trials performed under IND#14,247 (Food and Drug Administration)). With reference to these standards,
30 determination of therapeutically effective dosages for ASS inhibitors to be used in the invention for depletion of intracellular AMP may be readily made by those of ordinary skill in the oncological art.

35 In general, daily administration or continuous infusion of ASS inhibitors at dosages less than those known to produce toxicities will be the preferred therapeutic

protocol to enhance the anti-metabolite activity of the drugs. Due to the unique sensitivity of MTase deficient cells to this method of treatment, it can be expected that dosages less than those tested in clinical trials of L-alanosine in treatment of MTase competent cells will be required, thus reducing toxicity to non-proliferating cells.

Non-malignant, MTase competent cells may also be protected from any effect of exposure to ASS inhibitors through administration of MTA or a suitable substrate analogue for use in adenine synthesis. Suitable compounds for use in this regard include MTA, 2'-5' dideoxyadenosine, 5'-deoxyadenosine, 2'-deoxy-5-deoxy-5'methylthioadenosine (see, e.g., Example II). It will be appreciated, however, that MTase competent cells are capable of producing adenine from metabolism of methylthioadenosine for replenishment of the AMP cellular pool and therefore would not be expected to be depleted of AMP to the same extent as MTase deficient cells.

The invention having been fully described, its practice is illustrated by the examples set forth below. It will be understood, however, that the examples do not limit the scope of the invention, which is defined by the appended claims. Standard abbreviations are used throughout the Examples, such as "ml" for milliliter, "h" for hour and "mg" for milligram.

30

EXAMPLE I

IN VIVO EFFECT OF L-ALANOSINE ON MTase DEFICIENT AND MTase COMPETENT HUMAN TUMOR XENOGRAFTS AFTER CONTINUOUS INFUSION

35 To evaluate the *in vivo* effect of L-alanosine on known human MTase deficient tumors after continuous infusion, and to compare that effect to the drug's effect on known

human MTase competent tumors, 2×10^6 MTase deficient H292 NSCLC cells and MTase competent Calu-6 tumor cells (in 0.3 ml with 50% MATRIGEL™ carrier), were injected into the right and left flank, respectively, of 8 Balb/C athymic nude mice. MATRIGEL™ initially forms a solid matrix in vivo that was measured in each mouse on the first day of infusion for a control tumor size (which is resorbed over a 14-day period). For further comparison, 10^7 CEM T-ALL (MTase deficient acute lymphoblastic leukemia) cells in 50% MATRIGEL™ carrier were injected into the right flank of 8 other nude mice. Many of the cells were obtained from commercially available cell lines from the ATCC sold under, respectively, ATCC Accession Nos. CRL-1848 and HTB-56.

15

The following day, 4 mice with bilateral NSCLC and 4 with T-ALL inocula were implanted subcutaneously with ALZET™ 1007D osmotic infusion pumps in the back at a distance from tumor cell inoculation sites. The pumps had been filed with L-alanosine at a concentration calculated to deliver 60 mg/kg daily by continuous infusion. Because no toxicity was evident after 7 days at the 60 mg/kg dosage, the pumps were removed and replaced with pumps containing L-alanosine for delivery of 90 mg/kg per day for an additional 7 days.

As shown in FIGURE 2 and FIGURE 3, the administered L-alanosine caused the shrinkage of established MTase deficient NSCLC ("H292 L-alan Tx"; FIGURE 2) and T-ALL ("Treated mice"; FIGURE 3) xenograft inocula in immunodeficient murine hosts and prevented the growth of recent MTase-deficient NSCLC or T-ALL xenograft inocula in immunodeficient murine hosts as compared to treated MTase competent NSCLC cells and untreated MTase-deficient cells. In particular, established MTase competent tumors grew rapidly despite L-alanosine, as did untreated MTAP-deficient NSCLC or T-ALL xenografts.

EXAMPLE II
PROTECTION OF MTase COMPETENT HEALTHY
CELLS WITH MTase SUBSTRATES

5 The selective inability of MTase deficient NSCLC cells to proliferate in the presence of L-alanosine (at 40 μ M) despite the addition to each culture of the MTase substrate methylthioadenosine (MTA) was confirmed in a comparison of two cell lines, MTase competent Calu-6 and
10 MTase deficient H292 (FIGURE 4). Control cultures containing adenine (tAd) proliferate despite L-alanosine, confirming that the selective toxicity is due to a failure of MTase-deficient cells to metabolize MTA to adenine.

15

For further comparison, the addition of MTA or the MTA substrate analogue 5'-deoxyadenosine resulted in growth restoration only for MTase competent A427 cells and MOLT-4 cells, whereas MTase deficient A549 and CEM cells
20 remained growth inhibited (FIGURE 5A and B). Because MTA is a feedback inhibitor of spermine synthetase, some cell lines such as MOLT-4 are inhibited by high concentrations. This results in a biphasic growth restoration curve with increasing MTA concentration
25 (FIGURE 5A).

EXAMPLE III
CLONING AND PARTIAL CHARACTERIZATION
OF THE MTase GENOMIC CLONE

30

A genomic clone of human MTase was isolated as follows. A cosmid gene library constructed from human placenta DNA (Clontech) was screened using MTase cDNA gene probe, the Not I/EcoRI fragment from subclone MTAP-7. Transformed
35 *E. coli* cells from the library are plated on LB plates containing ampicillin (50 mg/l) with a colony density of $1-2 \times 10^4$ /135 x 15 mm plate.

The following procedures were performed. From half a million colonies, a single positive colony designated as MTAP-10 was isolated and partially characterized by PCR analysis and by direct sequencing. Two primers, a sense
5 oligonucleotide located 120 bp upstream of the stop codon and an anti-sense oligonucleotide located 20 bp downstream of the stop codon were synthesized and used for PCR analysis. PCR was performed for 25 cycles, each cycle consisting of denaturation (92°C, 1 min), annealing
10 (55°C, 2 min) and extension (72°C, 5 min). The PCR products were separated on a 0.8% agarose gel.

The location of exons identified to date in the MTase gene using the above-described technique is depicted in
15 FIGURE 1 by underlining.

EXAMPLE IV

APPLICATION OF MTase SEQUENCE-SPECIFIC OLIGONUCLEOTIDES TO MALIGNANT CELL LINES TO DETECT THE PRESENCE 20 OR ABSENCE OF MTase THEREIN

To test the usefulness of oligonucleotide probes developed from the MTase genomic clone identified as described in Example IV (SEQ.ID.No. 1), PCR was applied
25 to several human lung cancer cell lines which were known to contain MTase competent (Calu-6; ATCC Designation No. HTB-56) and deficient cells (A549; ATCC Designation No. CCL-185). Genomic DNA was isolated as described in Example III and 1 microgram thereof was used for PCR.

30 Amplification was performed for 40 cycles as described above, with each cycle consisting of denaturation (92°C, 1 min), annealing (55°C, 1 min), and extension (72°C, 1/2 min). The PCR products were analyzed on a 1.5% agarose
35 gel. No MTase was detected in cell lines which were known to be MTase deficient, while MTase was detected in the MTase competent cell lines.

EXAMPLE VL-ALANOSINE INHIBITION OF MTAP-DEFICIENT TUMORS
AFTER DAILY INJECTION INTO NUDE MICE
WITH ESTABLISHED TUMOR XENOGRAFTS

5

10⁷ A549 or A427 NSCLC cells were injected subcutaneously into 6-week old Balb/c athymic nude mice. When tumors had reached approximately 0.4 cm diameter, treatment was begun with L-alanosine or saline by intraperitoneal
10 injection every 12 hours.

Mice received 15 mg/kg per injection for 7 days then 22.5 mg/kg for 5 days. Tumor size was measured as the product of perpendicular diameters. The results for treated (n=6
5 [sample size] for each cell type) vs. control (n=4 [sample size] for each cell type) mice are shown in FIGURE 7.

No toxicity was evident at either dosing level tested
10 (mice had stable weights throughout testing). L-alanosine administered by twice daily bolus injection caused a decrease in the size of well-established MTAP-deficient tumors, but had no effect on the growth of MTAP-positive cells.

15

SUMMARY OF SEQUENCES

SEQUENCE ID. NO. 1 is the genomic clone for
methylthioadenosine phosphorylase (MTase).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

(ii) TITLE OF INVENTION: METHOD FOR INHIBITING ADENYLOSUCCINATE SYNTHETASE ACTIVITY IN
MALIGNANT METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Robbins, Berliner & Carson
(B) STREET: 201 N. Figueroa Street, 5th Floor
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90012-2628

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Berliner, Robert
(B) REGISTRATION NUMBER: 20,121
(C) REFERENCE/DOCKET NUMBER: 5555-423

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (213) 977-1001
(B) TELEFAX: (213) 977-1003

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2763 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vii) IMMEDIATE SOURCE:

- (B) CLONE: methyladenosine phosphatase

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2763

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TTTATACAGA GCATGACAGT GGGGTCTCA CTAGGGTCTG TCTGCCACTC TACATATTTG	60
AAACAGGAGT GGCTTCTCAG AATCCAGTGA ACCTAAATTT TAGTTTGTAG TGCTCACTGG	120
ACTGGGTCTT AGGAGACCCC CTGTGTTAGT CTGTGGTCAT TGCTAGSAGA ATCACTTAAT	180
TTTTTCTAGA CTCTAGGAGA AAACAGTTGG TGGTGTACTC ATCACGGGTT AACAAATTTCT	240
TCTCTCCTTC CATAGGCATG GAAGGCAGCA CACCATCATG CCTTCAAAGG TCAACTACCA	300
GGCGAACATC TGGGCTTTGA AGGAAGAGGG CTGTACACAT GTCATAGTGA CCACAGCTTG	360
TGGCTCCTTG AGGGAGGAGA TTCAGCCCGG CGATATTGTC ATTATTGATC AGTTCATTGA	420
CANNNNNNNN NNNNNNNNNN GAGGTGACG GTATCGATAA GCTTTGTAAA CAATTGTCTT	480
TAGTTATCC AGAGGAATTG AGTCTGGAGT AAAGACCCAA ATATTGACCT AGATAAAGTT	540
GACTCACCAG CCCTCGGAGG ATGGAAAGAT GGCCTTAAAA TAAACAAAC AAAAACCTTT	600
TTTGCTTTAT TTTGTAGGAC CACTATGAGA CCTCAGTCCT TCTATGATGG AAGTCATTCT	660
TGTGCCAGAG GAGTGTGCCA TATCCAATG GCTGAGCCGT TTTGCCCAA AACGAGAGAG	720
GTGTGTAGTC TTTCTGGAAG GTGTACCAGA ATAAATCATG TGGGCTTGGG GTGGCATCTG	780
GCATTTGGTT AATTGGCAGA CGBAGTGGCC CCATACCCTC ACTCAAGTTT GCTTTGTATT	840
ATGCAAGTTT ATGGAGAGTT ATTTCCTGTT GCTAATAATT YNNNNNNNNN NNNNNNNNNN	900
AAGTGACGCC TTAAGTTGTG CATGTGCTAG TATGTTTTGA AGTTTCTGGT TTTTCTTTTC	960
TAGTTCTTA TAGAGACTGC TAAGAAGCTA GGACTCCGGT GCCACTCAA GGGGACAATG	1020
GTCACAATCG AGGGACCTCG TTTTAGCTCC CGGGCAGAAA GCTTCATGTT CCGCACCTGG	1080
GGGGCGGATG TTATCAACAT GACCACAGTT CCAGAGGTGG TTCTTGCTAA GGAGGCTGGA	1140
ATTTGTTACG CAAGTATCGC CATGGGCACA GATTATGACT GCTGGAAGGA GCACGAGGAA	1200
GCAGTAGGTG GAATTCTTTT CTAAGCACAT ATAGCATGGG TTTCTGGGTG CCAATAGGGT	1260
GTCCTAAGTG TTTGTTTCTA TTACGTTAGT TTCAGAAAGT GCCTTTCTAC AAGGTTTTGA	1320
AGTTGTTAAT ATTTTCTGTA GTTCCATTGG AAGTAAGAA CAAAGATCAA AAGAAAGAAA	1380
GAGACACTTT TACCCAAGGA TCAGTAGTGA AAATAGTACA TTGTAGGCAT GTAGATGTGT	1440
TGAGAATCAT ACTAAGACTT GGGCCTTANN NNNNNNNNNN NNNNNNNNN NNTACCCTAC	1500
ATTGAGGATT CGGTTTCAGC AGATAAATTT GAGGGACACA AACATTTAGG CTGTAGCAAG	1560
GCTGGAGCTC AGAAAAATGT TTTATGACAA GCAGTGGAA TTTAAGTTCT AGTAACCTCC	1620
AGTGCTATTG TTTCTCTAGG TTTGGGTGGA CCGGGTCTTA AAGACCCTGA AAGAAAACGC	1680

TAATAAGCC AAAAGCTTAC TGCTCACTAC CATACCTCAG ATAGGGTCCA CAGAATGGTC	1740
AGAAACCCCTC CATAACCTGA AGGTAAGTGC AGCCATGGAC AATCAGGCAT GTCTGTAGAC	1800
TCTCTATTGT CTTCCTTTCT TACTTGCATT TCACCTTYGG TCCTCATGTA TTTTTTGCCA	1860
GCCTAGATGT TTTCAACAAG TTTTGTGAC ATCTACTACT ACCATACCAA CCACTTGTGA	1920
AACTGAGTAG TCTTATTTTC TTGGCTGGTA GTGCAGAMNN NNNNNNNNNN NNAATAAACA	1980
ATAATCCAGG CTGGGCTGGT ATGGCAATAA GTGATTATCA GAACAATGCT CTGAGATAAG	2040
CATTATTAAC CTCACCTTAC AGGAAAGGGA GGTGAGGAAC CAAGAGTTTA GAGTACCEGA	2100
AGTTCACAT CTGGTTAGTG AACTTGAAAA TTTCTGTAG AATTATTTA AAGTGATGT	2160
TYCCTGCGTC CTCACCTTGA TCTAGAAAT CAAAATCTGT TTTTTTTTTT AACAAACATC	2220
TCAGTAATTA CGCCAACATG TGAATATCAC TGCCTCCTTT CTTCCTTTCA GAATATGGCC	2280
CAGTTTTCTG TTTTATTACC AAGACATTAA AGTAGCATGG CTGCCAGGA GAAAAGAAGA	2340
CATTCTAATT CCACTCATT TGGGAATTC TGCTTAACCT GAAAAAATA TGGGAAGAC	2400
ATGCAGCTTT CATGCCCTG CCTATCAAAG AGTATGTTGT AAGAAAGACA AGACATTGTG	2460
TGTATAGAGA CTCTCAATG ATTTAGACAA CTTCAAAATA CAGAAGAAAA GCAATGACT	2520
AGTAACATGT GGGAAAAAT ATTACATTTT AAGGGGGAAA AAAAACCCCA CCATTCTCTT	2580
CTCCCCCTAT TAAATTTGCA ACAATAAAGG GTGGAGGGTA ATCTCTACTT TCCTATACTG	2640
CCAAAGAATG TGAGGAAGAA ATGGGACTCT TTGGTTATTT ATTGATGCGA CTGTAAATTG	2700
GTACAGTATT TCTGGAGGCG AATTTGGTAA AATGCATCAA AAGACTTAAA AATACGGACG	2760
TAC	2763



CLAIMS

1. A method for inhibiting the activity of adenyl succinate synthetase (ASS) in methythioadenosine phosphorylase (MTAse) deficient cells comprising:
 - (a) determining that a population of cells obtained from a mammalian host is MTAse deficient; and,
 - (b) administering a therapeutically effective amount of an ASS inhibitory agent to the host, wherein said contact has the effect of depleting MTAse deficient host cells of adenosine 5'-monophosphate.
2. The method according to Claim 1 wherein step (a) is performed by:
 - (a) obtaining an assayable sample of cells which are suspected of being MTAse deficient;
 - (b) adding oligonucleotide probes which will specifically hybridize to any of the MTAse encoding nucleic acid present in the sample to the sample under conditions which will allow the probes to detectably hybridize to any such nucleic acid present in the sample; and,
 - (c) detecting whether MTAse encoding nucleic acid is present in the sample, wherein the presence of said nucleic acid is indicative of the presence of MTAse protein in the sample of cells.
3. The method according to Claim 1 wherein the ASS inhibitory agent is L-alanosine.
4. The method according to Claim 1 wherein the host is a human.



5. The method according to Claim 1 wherein the MTase deficient host cells are primary tumor cells selected from the group consisting of non-small cell lung cancer cells, acute lymphoblastic leukemia cells, glioma cells and urothelial tumor cells.
5
6. The method according to Claim 1 wherein the ASS inhibitory agent is administered to the host daily or continuously.
10
7. The method according to Claim 1 wherein a substrate for intracellular production of AMP is administered to the host after treatment of the host according to step (b).
15
8. A method for inhibiting the activity of adenylysuccinate synthetase (ASS) in cells of a mammalian host, which cells are known to be methythioadenosine phosphorylase (MTase) deficient, comprising administering a therapeutically effective amount of an ASS inhibitory agent to the host, wherein said contact has the effect of depleting MTase deficient host cells of adenosine 5'-monophosphate.
20
9. The method according to Claim 8 wherein the ASS inhibitory agent is L-alanosine.
25
10. The method according to Claim 8 wherein the host is a human.
30
11. The method according to Claim 8 wherein the MTase deficient host cells are primary tumor cells selected from the group consisting of non-small cell lung cancer cells, acute lymphoblastic leukemia cells and glioma cells.
35



12. The method according to Claim 8 wherein the ASS inhibitory agent is administered to the host daily or continuously.
- 5 13. The method according to Claim 8 wherein a substrate for intracellular production of AMP is administered to the host after administration of the ASS inhibitory agent to the host.

1/5

FIG. 1A

1	TTTATACAGA	GCATGACAGT	GGGGTCCTCA	CTAGGGTCTG	TCTGCCACTC
51	TACATATTTG	AAACAGGAGT	GGCTTCTCAG	AATCCAGTGA	ACCTAAATTT
101	TAGTTTTAGT	TGCTCACTGG	ACTGGGTTCT	AGGAGACCCC	CTGTGTTAGT
151	CTGTGGTCAT	TGCTAGSAGA	ATCACTTAAT	TTTTTCTAGA	CTCTAGGAGA
201	AAACAGTTGG	TGGTGTACTC	ATCACGGGTT	AACAATTTCT	TCTCTCCTTC
251	<u>CATAGGCATG</u>	<u>GAAGGCAGCA</u>	<u>CACCATCATG</u>	<u>CCTTCAAAGG</u>	<u>TCAACTACCA</u>
301	<u>GGCGAACATC</u>	<u>TGGGCTTTGA</u>	<u>AGGAAGAGGG</u>	<u>CTGTACACAT</u>	<u>GTCATAGTGA</u>
351	<u>CCACAGCTTG</u>	<u>TGGCTCCTTG</u>	<u>AGGGAGGAGA</u>	<u>TTCAGCCCGG</u>	<u>CGATATTGTC</u>
401	<u>ATTATTGATC</u>	<u>AGTTCATTGA</u>	<u>CANNNNNNNN</u>	<u>NNNNNNNNNN</u>	<u>GAGGTCGACG</u>
451	GTATCGATAA	GCTTTGTAAA	CAATTGTCTT	TAGCTTATCC	AGAGGAATTG
501	AGTCTGGAGT	AAAGACCCAA	ATATTGACCT	AGATAAAGTT	GACTCACCAG
551	CCCTCGGAGG	ATGGAAAGAT	GGCCTTAAAA	TAAACAAAC	AAAAACCTTT
601	<u>TTTGCTTTAT</u>	<u>TTTGTAGGAC</u>	<u>CACTATGAGA</u>	<u>CCTCAGTCCT</u>	<u>TCTATGATGG</u>
651	<u>AAGTCATTCT</u>	<u>TGTGCCAGAG</u>	<u>GAGTGTGCCA</u>	<u>TATTCCAATG</u>	<u>GCTGAGCCGT</u>
701	<u>TTTGCCCCAA</u>	<u>AACGAGAGAG</u>	<u>GTGTGTAGTC</u>	<u>TTTCTGGAAG</u>	<u>GTGTACCAGA</u>
751	ATAAATCATG	TGGGCTTGGG	GTGGCATCTG	GCATTTGGTT	AATTGGCAGA
801	C6GAGTGGCC	CCATACCCTC	ACTCAAGTTT	GCTTTGTATT	ATGCAAGTTT
851	ATGGAGAGTT	ATTCCTGTT	GCTAATAATT	TNNNNNNNNN	NNNNNNNNNN
901	AAGTGCAGCC	TTAAGTTGTG	CATGTGCTAG	TATGTTTTGA	AGTTTCTGGT
951	<u>TTTTCTTTTC</u>	<u>TAGGTTCTTA</u>	<u>TAGAGACTGC</u>	<u>TAAGAAGCTA</u>	<u>GGACTCCGGT</u>
1001	<u>GCCACTCAAA</u>	<u>GGGGACAATG</u>	<u>GTCACAATCG</u>	<u>AGGGACCTCG</u>	<u>TTTTAGCTCC</u>
1051	<u>CGGGCAGAAA</u>	<u>GCTTCATGTT</u>	<u>CCGCACCTGG</u>	<u>GGGGCGGATG</u>	<u>TTATCAACAT</u>
1101	<u>GACCACAGTT</u>	<u>CCAGAGGTGG</u>	<u>TTCTTGCTAA</u>	<u>GGAGGCTGGA</u>	<u>ATTTGTTACG</u>
1151	<u>CAAGTATCGC</u>	<u>CATGGGCACA</u>	<u>GATTATGACT</u>	<u>GCTGGAAGGA</u>	<u>GCACGAGGAA</u>
1201	<u>GCAGTAGGTG</u>	<u>GAATTCTTTT</u>	<u>CTAAGCACAT</u>	<u>ATAGCATGGG</u>	<u>TTTCTGGGTG</u>
1251	CCAATAGGGT	GTCTTAAGTG	TTTGTCTCTA	TTACGTTAGT	TTCAGAAAGT
1301	GCCTTTCTAC	AAGGTTTTGA	AGTTGTTAAT	ATTTTCTGTA	GTTCCATTGG
1351	AAGGTAAGAA	CAAAGATCAA	AAGAAAGAAA	GAGACACTTT	TACCCAAGGA
1401	TCAGTAGTGA	AAATAGTACA	TTGTAGGCAT	GTAGATGTGT	TGAGAATCAT

2/5

FIG. 2





FIG. 3



3/5

FIG. 4





FIG. 5A



4/5

FIG. 5B






FIG. 7



5/5

FIG. 6



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12Q 1/02, 1/00, 1/42, G01N 33/567, 33/574	A1	(11) International Publication Number: WO 97/32994 (43) International Publication Date: 12 September 1997 (12.09.97)																																																																																																																																																																														
(21) International Application Number: PCT/US97/01193 (22) International Filing Date: 27 January 1997 (27.01.97) (30) Priority Data: 08/612,542 8 March 1996 (08.03.96) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). <i>Refer to form</i> (72) Inventors: CARRERA, Carlos, J.; 3924 Canning Avenue, San Diego, CA 92111 (US); CARSON, Dennis, A.; 14824 Vista del Oceano, Del Mar, CA 92014 (US); COTTAM, Howard, B.; 208 White Horse Lane, Fallbrook, CA 92028 (US); NOBORI, Tsutomu; 10666 Brookhollow Court, San Diego, CA 92126 (US). (74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>																																																																																																																																																																														
(54) Title: METHOD FOR INHIBITING ADENYLOSUCCINATE SYNTHETASE ACTIVITY METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS																																																																																																																																																																																
(57) Abstract An <i>in vivo</i> method for depleting mammalian cells of adenosine 5'-monophosphate (AMP) useful in the treatment of certain cancers is provided. According to the method, a population of cells is obtained from a host and assayed for loss of methylthioadenosine phosphorylase (MTase) activity. MTase catabolizes methylthioadenosine to adenine for endogenous salvage incorporation into the intracellular AMP pool. The preferred method for assaying loss of MTase activity is a hybridization technique for detection of a homozygous loss of the gene which encodes with a therapeutically effective amount of an agent which inhibits the activity of adenylosuccinate synthetase, which converts inosine 5'-monophosphate to AMP, thus depleting the tumor cells of substrates for <i>de novo</i> AMP production. L-alanosine is the preferred ASS inhibitory agent for use in the method of the invention. The figure is a nucleotide sequence for genomic MTase (SEQ. ID. No. 1) wherein the exons are underlined. <table border="0"> <tr> <td>1</td> <td>TTTATACAGA</td> <td>SCATGACAGT</td> <td>GGGGTCTCA</td> <td>CTAGGGTCTG</td> <td>TGTGCCACTC</td> </tr> <tr> <td>51</td> <td>TACATATTTS</td> <td>AACAGGAGT</td> <td>GGCTTCTCAG</td> <td>AATCCAGTGA</td> <td>ACCTAATTTT</td> </tr> <tr> <td>101</td> <td>TAGTTTAAAT</td> <td>TGCTCACTGG</td> <td>ACTGGTTCTT</td> <td>AGGAGACCCC</td> <td>CTGTGTTAGT</td> </tr> <tr> <td>151</td> <td>CTGTGTCAT</td> <td>TGCTAGSAGA</td> <td>ATCACTTAAT</td> <td>TTTTCTAGA</td> <td>CTCTAGGAGA</td> </tr> <tr> <td>201</td> <td>AACAGTTGG</td> <td>TGTTGACTC</td> <td>ATCAGGGTT</td> <td>AACAATTTCT</td> <td>TCTCTCTTC</td> </tr> <tr> <td>251</td> <td>CATAGCATG</td> <td>GAAGCAGCA</td> <td>CAGCATGATG</td> <td>CTTCAAGG</td> <td>TCAGCTACCA</td> </tr> <tr> <td>301</td> <td>GGCAACATC</td> <td>TGGCTTTGA</td> <td>AGGAGAGGG</td> <td>CTGTACACAT</td> <td>ATCATAGTGA</td> </tr> <tr> <td>351</td> <td>CCACAGCTG</td> <td>TGGCTCTG</td> <td>AGGAGAGGA</td> <td>TTCAAGCCCG</td> <td>CAATATTTCT</td> </tr> <tr> <td>401</td> <td>ATTATTATC</td> <td>AGTTCAATG</td> <td>CANNNNNNN</td> <td>NNNNNNNN</td> <td>GAGGTGACG</td> </tr> <tr> <td>451</td> <td>GTATCGATA</td> <td>GCTTTGTAA</td> <td>CAATGTCTT</td> <td>TAGCTTATCC</td> <td>AGAGSAATTG</td> </tr> <tr> <td>501</td> <td>AGTCTGAGT</td> <td>AAGACCCAA</td> <td>ATATTGACCT</td> <td>AGATAAGATT</td> <td>GACTCAGCAG</td> </tr> <tr> <td>551</td> <td>CCCTCGAGG</td> <td>ATGGAAGAT</td> <td>GGCTTAAAA</td> <td>TAAACAAAC</td> <td>AAAAACCTTT</td> </tr> <tr> <td>601</td> <td>TTTGCTTTAT</td> <td>TTTGAGGAC</td> <td>CAGTATBAGA</td> <td>CTTCAATCT</td> <td>TCTATGATGG</td> </tr> <tr> <td>651</td> <td>AAGTCAITCT</td> <td>TGTGCGAG</td> <td>AGGTGTGCA</td> <td>TATCCCAATG</td> <td>GCTBAGCCAT</td> </tr> <tr> <td>701</td> <td>TTTGCCCAA</td> <td>AACAGAGAG</td> <td>GTTGTATGC</td> <td>TTTCTGAGG</td> <td>GTTGACCAGA</td> </tr> <tr> <td>751</td> <td>ATAAATCATG</td> <td>TGGCTTGGG</td> <td>GTCGACATG</td> <td>GCATTGTGTT</td> <td>AATYGGCAGA</td> </tr> <tr> <td>801</td> <td>CGGATGACC</td> <td>CCATACCTC</td> <td>ACTCAAGTT</td> <td>GCTTGTATT</td> <td>ATGCAAGTTT</td> </tr> <tr> <td>851</td> <td>ATGAGAGTT</td> <td>ATTCTCTTT</td> <td>GCTAATAAT</td> <td>TNNNNNNNN</td> <td>NNNNNNNN</td> </tr> <tr> <td>901</td> <td>AAGTCAGCC</td> <td>TAAATTTGG</td> <td>CATGCTAG</td> <td>TATGTTTGA</td> <td>AGTTTCTGCT</td> </tr> <tr> <td>951</td> <td>TTTTCTTTT</td> <td>TAGTTCTTA</td> <td>TAGAGACTG</td> <td>TAGAGACTA</td> <td>GGACTGCGT</td> </tr> <tr> <td>1001</td> <td>GCATTCAG</td> <td>GGGACATG</td> <td>GTCAATG</td> <td>AGGACTCTG</td> <td>TTTTAGCTCC</td> </tr> <tr> <td>1051</td> <td>GGGACAGAA</td> <td>GCCTCATTT</td> <td>CGGACTTGG</td> <td>GGGCGGATG</td> <td>TTATCAGAT</td> </tr> <tr> <td>1101</td> <td>GAGCAGATT</td> <td>CGAGAGTGG</td> <td>TCTTCTCAA</td> <td>GGAGCTTGA</td> <td>ATTGTTTACG</td> </tr> <tr> <td>1151</td> <td>CAGTATGCG</td> <td>CATGCGACA</td> <td>GATTATGAT</td> <td>GCTGAGGGA</td> <td>GCAGAGGAA</td> </tr> <tr> <td>1201</td> <td>GGGTAGGAG</td> <td>GAATCTTTT</td> <td>CTAGCAGAT</td> <td>ATAGCATGG</td> <td>TTTCTGGG</td> </tr> <tr> <td>1251</td> <td>CCAATAGGT</td> <td>GTCTTACTG</td> <td>TTTGTCTTA</td> <td>TACGTTAAT</td> <td>TTCAAGAGT</td> </tr> <tr> <td>1301</td> <td>GCCTTCTAC</td> <td>AAGGTTTGA</td> <td>AGTTGTAAT</td> <td>ATTTCTGTA</td> <td>GTTCATTTG</td> </tr> <tr> <td>1351</td> <td>AAGTAAAG</td> <td>CAAGATCAA</td> <td>AAGAAAGAA</td> <td>CAGACACTT</td> <td>TACCAAGGA</td> </tr> <tr> <td>1401</td> <td>TGATAGTGA</td> <td>AAATAGTACA</td> <td>TGTAGGCAT</td> <td>GATAGTGT</td> <td>TGAGATCAT</td> </tr> </table>			1	TTTATACAGA	SCATGACAGT	GGGGTCTCA	CTAGGGTCTG	TGTGCCACTC	51	TACATATTTS	AACAGGAGT	GGCTTCTCAG	AATCCAGTGA	ACCTAATTTT	101	TAGTTTAAAT	TGCTCACTGG	ACTGGTTCTT	AGGAGACCCC	CTGTGTTAGT	151	CTGTGTCAT	TGCTAGSAGA	ATCACTTAAT	TTTTCTAGA	CTCTAGGAGA	201	AACAGTTGG	TGTTGACTC	ATCAGGGTT	AACAATTTCT	TCTCTCTTC	251	CATAGCATG	GAAGCAGCA	CAGCATGATG	CTTCAAGG	TCAGCTACCA	301	GGCAACATC	TGGCTTTGA	AGGAGAGGG	CTGTACACAT	ATCATAGTGA	351	CCACAGCTG	TGGCTCTG	AGGAGAGGA	TTCAAGCCCG	CAATATTTCT	401	ATTATTATC	AGTTCAATG	CANNNNNNN	NNNNNNNN	GAGGTGACG	451	GTATCGATA	GCTTTGTAA	CAATGTCTT	TAGCTTATCC	AGAGSAATTG	501	AGTCTGAGT	AAGACCCAA	ATATTGACCT	AGATAAGATT	GACTCAGCAG	551	CCCTCGAGG	ATGGAAGAT	GGCTTAAAA	TAAACAAAC	AAAAACCTTT	601	TTTGCTTTAT	TTTGAGGAC	CAGTATBAGA	CTTCAATCT	TCTATGATGG	651	AAGTCAITCT	TGTGCGAG	AGGTGTGCA	TATCCCAATG	GCTBAGCCAT	701	TTTGCCCAA	AACAGAGAG	GTTGTATGC	TTTCTGAGG	GTTGACCAGA	751	ATAAATCATG	TGGCTTGGG	GTCGACATG	GCATTGTGTT	AATYGGCAGA	801	CGGATGACC	CCATACCTC	ACTCAAGTT	GCTTGTATT	ATGCAAGTTT	851	ATGAGAGTT	ATTCTCTTT	GCTAATAAT	TNNNNNNNN	NNNNNNNN	901	AAGTCAGCC	TAAATTTGG	CATGCTAG	TATGTTTGA	AGTTTCTGCT	951	TTTTCTTTT	TAGTTCTTA	TAGAGACTG	TAGAGACTA	GGACTGCGT	1001	GCATTCAG	GGGACATG	GTCAATG	AGGACTCTG	TTTTAGCTCC	1051	GGGACAGAA	GCCTCATTT	CGGACTTGG	GGGCGGATG	TTATCAGAT	1101	GAGCAGATT	CGAGAGTGG	TCTTCTCAA	GGAGCTTGA	ATTGTTTACG	1151	CAGTATGCG	CATGCGACA	GATTATGAT	GCTGAGGGA	GCAGAGGAA	1201	GGGTAGGAG	GAATCTTTT	CTAGCAGAT	ATAGCATGG	TTTCTGGG	1251	CCAATAGGT	GTCTTACTG	TTTGTCTTA	TACGTTAAT	TTCAAGAGT	1301	GCCTTCTAC	AAGGTTTGA	AGTTGTAAT	ATTTCTGTA	GTTCATTTG	1351	AAGTAAAG	CAAGATCAA	AAGAAAGAA	CAGACACTT	TACCAAGGA	1401	TGATAGTGA	AAATAGTACA	TGTAGGCAT	GATAGTGT	TGAGATCAT
1	TTTATACAGA	SCATGACAGT	GGGGTCTCA	CTAGGGTCTG	TGTGCCACTC																																																																																																																																																																											
51	TACATATTTS	AACAGGAGT	GGCTTCTCAG	AATCCAGTGA	ACCTAATTTT																																																																																																																																																																											
101	TAGTTTAAAT	TGCTCACTGG	ACTGGTTCTT	AGGAGACCCC	CTGTGTTAGT																																																																																																																																																																											
151	CTGTGTCAT	TGCTAGSAGA	ATCACTTAAT	TTTTCTAGA	CTCTAGGAGA																																																																																																																																																																											
201	AACAGTTGG	TGTTGACTC	ATCAGGGTT	AACAATTTCT	TCTCTCTTC																																																																																																																																																																											
251	CATAGCATG	GAAGCAGCA	CAGCATGATG	CTTCAAGG	TCAGCTACCA																																																																																																																																																																											
301	GGCAACATC	TGGCTTTGA	AGGAGAGGG	CTGTACACAT	ATCATAGTGA																																																																																																																																																																											
351	CCACAGCTG	TGGCTCTG	AGGAGAGGA	TTCAAGCCCG	CAATATTTCT																																																																																																																																																																											
401	ATTATTATC	AGTTCAATG	CANNNNNNN	NNNNNNNN	GAGGTGACG																																																																																																																																																																											
451	GTATCGATA	GCTTTGTAA	CAATGTCTT	TAGCTTATCC	AGAGSAATTG																																																																																																																																																																											
501	AGTCTGAGT	AAGACCCAA	ATATTGACCT	AGATAAGATT	GACTCAGCAG																																																																																																																																																																											
551	CCCTCGAGG	ATGGAAGAT	GGCTTAAAA	TAAACAAAC	AAAAACCTTT																																																																																																																																																																											
601	TTTGCTTTAT	TTTGAGGAC	CAGTATBAGA	CTTCAATCT	TCTATGATGG																																																																																																																																																																											
651	AAGTCAITCT	TGTGCGAG	AGGTGTGCA	TATCCCAATG	GCTBAGCCAT																																																																																																																																																																											
701	TTTGCCCAA	AACAGAGAG	GTTGTATGC	TTTCTGAGG	GTTGACCAGA																																																																																																																																																																											
751	ATAAATCATG	TGGCTTGGG	GTCGACATG	GCATTGTGTT	AATYGGCAGA																																																																																																																																																																											
801	CGGATGACC	CCATACCTC	ACTCAAGTT	GCTTGTATT	ATGCAAGTTT																																																																																																																																																																											
851	ATGAGAGTT	ATTCTCTTT	GCTAATAAT	TNNNNNNNN	NNNNNNNN																																																																																																																																																																											
901	AAGTCAGCC	TAAATTTGG	CATGCTAG	TATGTTTGA	AGTTTCTGCT																																																																																																																																																																											
951	TTTTCTTTT	TAGTTCTTA	TAGAGACTG	TAGAGACTA	GGACTGCGT																																																																																																																																																																											
1001	GCATTCAG	GGGACATG	GTCAATG	AGGACTCTG	TTTTAGCTCC																																																																																																																																																																											
1051	GGGACAGAA	GCCTCATTT	CGGACTTGG	GGGCGGATG	TTATCAGAT																																																																																																																																																																											
1101	GAGCAGATT	CGAGAGTGG	TCTTCTCAA	GGAGCTTGA	ATTGTTTACG																																																																																																																																																																											
1151	CAGTATGCG	CATGCGACA	GATTATGAT	GCTGAGGGA	GCAGAGGAA																																																																																																																																																																											
1201	GGGTAGGAG	GAATCTTTT	CTAGCAGAT	ATAGCATGG	TTTCTGGG																																																																																																																																																																											
1251	CCAATAGGT	GTCTTACTG	TTTGTCTTA	TACGTTAAT	TTCAAGAGT																																																																																																																																																																											
1301	GCCTTCTAC	AAGGTTTGA	AGTTGTAAT	ATTTCTGTA	GTTCATTTG																																																																																																																																																																											
1351	AAGTAAAG	CAAGATCAA	AAGAAAGAA	CAGACACTT	TACCAAGGA																																																																																																																																																																											
1401	TGATAGTGA	AAATAGTACA	TGTAGGCAT	GATAGTGT	TGAGATCAT																																																																																																																																																																											